• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Phathom Pharmaceuticals Announces Appointment of Molly Henderson as Chief Financial and Business Officer

    3/22/22 8:02:00 AM ET
    $CALT
    $PHAT
    $URGN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CALT alert in real time by email

    FLORHAM PARK, N.J., March 22, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced the appointment of Molly Henderson to the position of Chief Financial and Business Officer. Ms. Henderson will join the Company effective April 5, 2022.      

    Ms. Henderson most recently served as Chief Financial Officer of UroGen Pharma (NASDAQ:URGN), a commercial-stage biopharmaceutical company focused on building novel treatments for specialty cancers and urologic disease. She brings over two decades of global finance expertise and has extensive experience in financial planning and analysis, investor relations, and capital raising.

    "Molly brings to Phathom deep financial acumen and significant industry experience across mid-size and large-scale commercial organizations, and we are excited to have her join our executive leadership team," said Terrie Curran, President and Chief Executive Officer of Phathom. "Phathom's corporate finance, strategy, and business development capabilities will be further enhanced through Molly's leadership as we accelerate our evolution into a commercial stage company."

    Ms. Henderson has extensive experience in the pharmaceutical industry and currently serves as a member of the Board of Directors and Chair of the Audit Committee of Calliditas Therapeutics AB (NASDAQ:CALT). She was previously the Chief Financial Officer and Executive Vice President of Advaxis, Inc., Chief Financial Officer of Iovance Biotherapeutics, Inc. (formerly Lion Biotechnologies, Inc.), and prior to then, the Chief Business and Financial Officer and Senior Vice President of VirtualScopics, Inc. Ms. Henderson holds an MBA and MS in Accounting from the State University of New York at Buffalo.

    About Phathom

    Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases and disorders. Phathom has in-licensed the exclusive rights in the United States, Europe, and Canada to vonoprazan, a novel potassium competitive acid blocker (P-CAB) in late-stage development for the treatment of acid-related disorders. For more information about Phathom, visit the Company's website at www.phathompharma.com and follow the Company on LinkedIn and Twitter.

    CONTACTS

    Media Contact:

    Nick Benedetto

    1-877-742-8466

    [email protected] 

    Investor Contact:

    Joe Hand

    1-877-742-8466

    [email protected]



    Primary Logo

    Get the next $CALT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CALT
    $PHAT
    $URGN

    CompanyDatePrice TargetRatingAnalyst
    UroGen Pharma Ltd.
    $URGN
    4/16/2025$23.00Sector Outperform
    Scotiabank
    UroGen Pharma Ltd.
    $URGN
    2/19/2025$31.00Buy
    Ladenburg Thalmann
    Phathom Pharmaceuticals Inc.
    $PHAT
    2/14/2025$23.00Overweight
    Cantor Fitzgerald
    UroGen Pharma Ltd.
    $URGN
    8/22/2024$40.00Buy
    Guggenheim
    Phathom Pharmaceuticals Inc.
    $PHAT
    5/3/2024$24.00Buy
    Stifel
    Phathom Pharmaceuticals Inc.
    $PHAT
    1/5/2024$23.00 → $26.00Buy
    Needham
    Phathom Pharmaceuticals Inc.
    $PHAT
    8/9/2023$28.00Buy
    H.C. Wainwright
    Calliditas Therapeutics AB
    $CALT
    6/20/2023$60.00Buy
    H.C. Wainwright
    More analyst ratings

    $CALT
    $PHAT
    $URGN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Scotiabank initiated coverage on UroGen Pharma with a new price target

      Scotiabank initiated coverage of UroGen Pharma with a rating of Sector Outperform and set a new price target of $23.00

      4/16/25 8:14:26 AM ET
      $URGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ladenburg Thalmann resumed coverage on UroGen Pharma with a new price target

      Ladenburg Thalmann resumed coverage of UroGen Pharma with a rating of Buy and set a new price target of $31.00

      2/19/25 7:08:16 AM ET
      $URGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cantor Fitzgerald initiated coverage on Phathom Pharmaceuticals with a new price target

      Cantor Fitzgerald initiated coverage of Phathom Pharmaceuticals with a rating of Overweight and set a new price target of $23.00

      2/14/25 7:06:18 AM ET
      $PHAT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CALT
    $PHAT
    $URGN
    Leadership Updates

    Live Leadership Updates

    See more
    • Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      FLORHAM PARK, N.J., May 01, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced that, in connection with the appointment of Jonathan Bentley as Senior Vice President, Head of Sales, the Company's Board of Directors has approved the grant of inducement awards. On May 1, 2025, the Company's Board of Directors granted inducement awards to Mr. Bentley under the Company's 2025 Employment Inducement Incentive Award Plan (the "Inducement Plan"). Mr. Bentley was granted a non-qualified stock option to purchase 79,365 shares of Phathom common

      5/1/25 4:15:59 PM ET
      $PHAT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Frazier Life Sciences Appoints Aditya Kohli to Partner

      Frazier Life Sciences (FLS), a longstanding investment firm focused on innovative therapeutics, today announced the appointment of Aditya Kohli, Ph.D., to Partner. Since joining FLS in 2016, Dr. Kohli has played a foundational role in company creation, co-founding six life sciences companies, including HilleVax (NASDAQ:HLVX, IPO in 2022)), Phathom Pharmaceuticals (NASDAQ:PHAT, IPO in 2019)), and Scout Bio (acquired by Ceva Santé Animale). He previously acted as Chief Business Officer at Phathom, Chief Operating Officer at HilleVax, and served on the Board of Scout Bio. He currently serves on the Board of HilleVax. "Aditya has been a valued member of the FLS team, and we are thrilled to se

      4/17/25 8:00:00 AM ET
      $HLVX
      $PHAT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Phathom Pharmaceuticals Appoints Ted Schroeder to its Board of Directors

      FLORHAM PARK, N.J., April 16, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced the appointment of Ted Schroeder to its Board of Directors. Mr. Schroeder brings more than three decades of experience leading innovative biopharmaceutical companies and has a strong track record of building and scaling commercial organizations, bringing new therapies to market, and successfully guiding companies through key business milestones and strategic transactions. "We are pleased to welcome Ted to the Phathom Board during a pivotal period for the com

      4/16/25 8:00:46 AM ET
      $CDTX
      $PHAT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations

    $CALT
    $PHAT
    $URGN
    Financials

    Live finance-specific insights

    See more
    • UroGen Pharma to Report First Quarter 2025 Financial Results on Monday, May 12, 2025

      Conference Call and Webcast Scheduled for Monday, May 12, 2025, at 10:00 AM ET UroGen Pharma Ltd. (NASDAQ:URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will report first quarter 2025 financial results on Monday, May 12, 2025, prior to the open of the stock market. The announcement will be followed by a live audio webcast and conference call at 10:00 AM Eastern Time. A live public webcast of the earnings conference call can be accessed on UroGen's Investor Relations website. Following the live webcast, a replay will be available on the site for approximately 30 days. About UroG

      5/1/25 4:00:00 PM ET
      $URGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Phathom Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

      VOQUEZNA launch momentum continues with over 390,000 prescriptions filled to date, written by more than 23,600 healthcare providersNet revenues of $28.5 million reported for Q1Filled VOQUEZNA prescriptions increased ~8% in Q1 over the prior quarter despite seasonal headwindsStrategic cost reductions and executive leadership changes implemented to support sustainable revenue growth and achieve profit from operations, excluding stock-based compensation, in 2026Management to host conference call today, May 1, 2025, at 8:00 a.m. ET FLORHAM PARK, N.J., May 01, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on developing and commerciali

      5/1/25 7:00:41 AM ET
      $ITCI
      $PHAT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Phathom Pharmaceuticals to Report First Quarter 2025 Financial Results and Provide Business Update on Thursday, May 1, 2025

      • Management to host conference call on Thursday, May 1, 2025, at 8:00 am EDT FLORHAM PARK, N.J., April 23, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced that it will host a live webcast at 8:00 am EDT on Thursday, May 1, 2025, to report its first quarter 2025 financial results and provide a business update. A live webcast and additional information about the presentation can be accessed on the Events & Presentations section of the Phathom website at https://investors.phathompharma.com/news-events/events-and-presentations. A recordi

      4/23/25 8:00:22 AM ET
      $PHAT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CALT
    $PHAT
    $URGN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • UroGen Announces FDA Advisory Committee for UGN-102, an Investigational Treatment for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

      UroGen (NASDAQ:URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that the U.S. Food and Drug Administration (FDA) has scheduled an Oncologic Drugs Advisory Committee (ODAC) meeting on May 21, 2025 to review the new drug application (NDA) for UGN-102 (mitomycin) for intravesical solution, an investigational treatment for recurrent LG-IR-NMIBC. The ODAC meeting will provide an opportunity for independent clinicians and other experts to evaluate the UGN-102 data and make a recommendation to the FDA as to whether the NDA should be approved and under what conditions. The FDA carefully considers

      5/7/25 8:57:00 AM ET
      $URGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      FLORHAM PARK, N.J., May 01, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced that, in connection with the appointment of Jonathan Bentley as Senior Vice President, Head of Sales, the Company's Board of Directors has approved the grant of inducement awards. On May 1, 2025, the Company's Board of Directors granted inducement awards to Mr. Bentley under the Company's 2025 Employment Inducement Incentive Award Plan (the "Inducement Plan"). Mr. Bentley was granted a non-qualified stock option to purchase 79,365 shares of Phathom common

      5/1/25 4:15:59 PM ET
      $PHAT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • UroGen Pharma to Report First Quarter 2025 Financial Results on Monday, May 12, 2025

      Conference Call and Webcast Scheduled for Monday, May 12, 2025, at 10:00 AM ET UroGen Pharma Ltd. (NASDAQ:URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will report first quarter 2025 financial results on Monday, May 12, 2025, prior to the open of the stock market. The announcement will be followed by a live audio webcast and conference call at 10:00 AM Eastern Time. A live public webcast of the earnings conference call can be accessed on UroGen's Investor Relations website. Following the live webcast, a replay will be available on the site for approximately 30 days. About UroG

      5/1/25 4:00:00 PM ET
      $URGN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CALT
    $PHAT
    $URGN
    SEC Filings

    See more
    • SEC Form 10-Q filed by Phathom Pharmaceuticals Inc.

      10-Q - Phathom Pharmaceuticals, Inc. (0001783183) (Filer)

      5/1/25 7:05:22 AM ET
      $PHAT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 8-K filed by Phathom Pharmaceuticals Inc.

      8-K - Phathom Pharmaceuticals, Inc. (0001783183) (Filer)

      5/1/25 7:05:17 AM ET
      $PHAT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form 10-K/A filed by UroGen Pharma Ltd.

      10-K/A - UroGen Pharma Ltd. (0001668243) (Filer)

      4/30/25 4:00:34 PM ET
      $URGN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CALT
    $PHAT
    $URGN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Parikh Asit bought $24,984 worth of shares (10,000 units at $2.50), increasing direct ownership by 12% to 95,500 units (SEC Form 4)

      4 - Phathom Pharmaceuticals, Inc. (0001783183) (Issuer)

      5/8/25 5:27:00 PM ET
      $PHAT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Parikh Asit bought $44,200 worth of shares (10,000 units at $4.42), increasing direct ownership by 13% to 85,500 units (SEC Form 4)

      4 - Phathom Pharmaceuticals, Inc. (0001783183) (Issuer)

      3/17/25 4:27:25 PM ET
      $PHAT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Karbe Frank bought $99,084 worth of shares (12,500 units at $7.93), increasing direct ownership by 28% to 57,000 units (SEC Form 4)

      4 - Phathom Pharmaceuticals, Inc. (0001783183) (Issuer)

      12/16/24 8:05:06 AM ET
      $PHAT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CALT
    $PHAT
    $URGN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $CALT
    $PHAT
    $URGN
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more

    $CALT
    $PHAT
    $URGN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Director Parikh Asit bought $24,984 worth of shares (10,000 units at $2.50), increasing direct ownership by 12% to 95,500 units (SEC Form 4)

      4 - Phathom Pharmaceuticals, Inc. (0001783183) (Issuer)

      5/8/25 5:27:00 PM ET
      $PHAT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • New insider Breedlove Robert Charles claimed ownership of 55,192 shares (SEC Form 3)

      3 - Phathom Pharmaceuticals, Inc. (0001783183) (Issuer)

      5/6/25 4:59:33 PM ET
      $PHAT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Schroeder Theodore R was granted 21,000 shares (SEC Form 4)

      4 - Phathom Pharmaceuticals, Inc. (0001783183) (Issuer)

      4/16/25 5:44:03 PM ET
      $PHAT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for VOQUEZNA issued to PHATHOM PHARMACEUTICALS INC

      Submission status for PHATHOM PHARMACEUTICALS INC's drug VOQUEZNA (ORIG-1) with active ingredient VONOPRAZAN FUMARATE has changed to 'Approval' on 07/17/2024. Application Category: NDA, Application Number: 218710, Application Classification: Type 9 - New Indication Submitted as Distinct NDA, Consolidated with Original NDA after Approval

      7/18/24 10:52:01 AM ET
      $PHAT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for VOQUEZNA TRIPLE PAK issued to PHATHOM PHARMACEUTICALS, INC

      Submission status for PHATHOM PHARMACEUTICALS, INC's drug VOQUEZNA TRIPLE PAK (ORIG-1) with active ingredient AMOXICILLIN; CLARITHROMYCIN; VONOPRAZAN has changed to 'Approval' on 05/03/2022. Application Category: NDA, Application Number: 215152, Application Classification: Type 1 - New Molecular Entity and Type 4 - New Combination

      5/11/22 10:51:07 AM ET
      $PHAT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for VOQUEZNA DUAL PAK issued to PHATHOM PHARMACEUTICALS, INC

      Submission status for PHATHOM PHARMACEUTICALS, INC's drug VOQUEZNA DUAL PAK (ORIG-1) with active ingredient AMOXICILLIN; VONOPRAZAN has changed to 'Approval' on 05/03/2022. Application Category: NDA, Application Number: 215153, Application Classification: Type 5 - New Formulation or New Manufacturer

      5/11/22 10:17:03 AM ET
      $PHAT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by UroGen Pharma Ltd.

      SC 13D/A - UroGen Pharma Ltd. (0001668243) (Subject)

      11/18/24 6:16:04 AM ET
      $URGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by UroGen Pharma Ltd.

      SC 13G/A - UroGen Pharma Ltd. (0001668243) (Subject)

      11/14/24 7:46:37 PM ET
      $URGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by UroGen Pharma Ltd.

      SC 13G/A - UroGen Pharma Ltd. (0001668243) (Subject)

      11/14/24 5:46:12 PM ET
      $URGN
      Biotechnology: Pharmaceutical Preparations
      Health Care